LGL Group, Inc. (The) (NYSEAMERICAN:LGL – Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 73,603 shares, a growth of 214.9% from the May 14th total of 23,373 shares. Approximately 1.4% of the company’s stock are short sold. Based on an average daily trading volume, of 18,493 shares, the days-to-cover ratio is presently 4.0 days.
LGL Group Stock Performance
Shares of LGL stock opened at $6.87 on Friday. LGL Group has a one year low of $5.45 and a one year high of $9.74. The company’s 50-day moving average is $7.05 and its 200 day moving average is $6.73. The company has a market capitalization of $44.93 million, a price-to-earnings ratio of 687.69 and a beta of 0.31.
LGL Group (NYSEAMERICAN:LGL – Get Free Report) last announced its quarterly earnings data on Monday, March 30th. The industrial products company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.09). LGL Group had a net margin of 1.66% and a return on equity of 0.16%. The firm had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $9.10 million. As a group, research analysts predict that LGL Group will post -0.06 earnings per share for the current fiscal year.
Institutional Trading of LGL Group
Analyst Ratings Changes
Separately, Zacks Research raised shares of LGL Group to a “hold” rating in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, LGL Group has a consensus rating of “Hold”.
Read Our Latest Stock Report on LGL Group
About LGL Group
LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.
The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.
Featured Articles
- Five stocks we like better than LGL Group
- Cooking Up Profits: Cracker Barrel’s Turnaround
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
Receive News & Ratings for LGL Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LGL Group and related companies with MarketBeat.com's FREE daily email newsletter.
